Consolidated figures · ₹ crore
| ₹ Cr | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 | |
| COGS | 4,040 | 4,495 | 5,554 | 6,079 | 7,442 | 7,658 | 8,209 | 9,980 | 12,239 |
| Gross profit | 10,242 | 10,953 | 11,963 | 12,969 | 14,103 | 17,012 | 19,802 | 22,664 | 21,461 |
| 7,856 | 7,731 | 9,436 | 9,051 | 10,265 | 10,626 | 11,855 | 14,095 | 14,994 | |
| 2,386 | 3,222 | 2,527 | 3,918 | 3,838 | 6,386 | 7,948 | 8,569 | 6,467 | |
| OPM % | 16.7% | 20.9% | 14.4% | 20.6% | 17.8% | 25.9% | 28.4% | 26.3% | 19.2% |
| Depreciation | 1,077 | 1,135 | 1,163 | 1,229 | 1,165 | 1,250 | 1,470 | 1,704 | 2,059 |
| Interest | 79 | 89 | 98 | 97 | 96 | 143 | 171 | 283 | 374 |
| 155 | 338 | 621 | 291 | 484 | 1,056 | 894 | 1,097 | 1,358 | |
| Profit before tax | 1,385 | 2,336 | 1,886 | 2,884 | 3,061 | 6,049 | 7,201 | 7,680 | 5,393 |
| Tax | 438 | 386 | -140 | 932 | 879 | 1,541 | 1,623 | 1,954 | 1,235 |
| Tax % | 31.6% | 16.5% | -7.4% | 32.3% | 28.7% | 25.5% | 22.5% | 25.5% | 22.9% |
| 947 | 1,950 | 2,026 | 1,952 | 2,183 | 4,507 | 5,578 | 5,725 | 4,158 | |
| PAT margin % | 6.6% | 12.6% | 11.6% | 10.3% | 10.1% | 18.3% | 19.9% | 17.5% | 12.3% |
| EPS (₹) | 57.1 | 117.5 | 122.2 | 117.7 | 131.6 | 271.5 | 335.2 | 67.9 | 50.4 |
| EPS adjusted (₹) | — | — | — | 23.5 | 26.2 | 54.1 | 66.9 | 67.8 | 50.3 |
| 35% | 17% | 20.5% | 21.2% | 22.8% | 14.7% | 11.9% | 11.8% | 15.9% | |
| Annual report | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 83 | 83 | 83 | 83 | 83 | 84 |
| Reserves | 17,559 | 19,129 | 23,203 | 28,171 | 33,466 | 37,808 |
| Minority interest | — | — | — | — | 378 | 339 |
| 2,695 | 3,088 | 1,347 | 1,652 | 4,185 | 6,294 | |
| 6,281 | 7,446 | 7,652 | 8,957 | 11,315 | 13,599 | |
| Total equity & liabilities | 26,617 | 29,747 | 32,285 | 38,864 | 49,427 | 58,123 |
| 8,206 | 8,122 | 9,219 | 10,426 | 18,226 | 22,063 | |
| CWIP | 954 | 1,280 | 975 | 1,351 | 2,399 | 1,460 |
| Investments | 2,212 | 2,616 | 4,986 | 4,931 | 4,051 | 5,285 |
| 15,245 | 17,730 | 17,105 | 22,157 | 24,750 | 29,315 | |
| Total assets | 26,617 | 29,747 | 32,285 | 38,864 | 49,427 | 58,123 |
As reported in NSE results XBRL. Segment result is before tax and finance costs.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities |
|---|---|---|---|---|
| Global Generics | 29,946 | 16,969.6 | 0 | 0 |
| Pharmaceutical Services and Active Ingredients | 4,267.2 | 600.2 | 0 | 0 |
| Others | 214 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 3,570 | 2,811 | 5,887 | 4,543 | 4,643 | 5,674 | |
| -2,266 | -2,639 | -4,137 | -4,028 | -5,102 | -6,549 | |
| -30 | -242 | -2,686 | -376 | 1,186 | 829 | |
| Net cash flow | 1,275 | -70 | -936 | 139 | 726 | -47 |
| Free cash flow | 2,596 | 1,345 | 4,755 | 2,903 | 1,892 | 3,343 |
| CFO / Operating profit % | 92.3% | 74.6% | 92.7% | 57.3% | 54.3% | 87.9% |
| 158.1 |
| 0 |
| 0 |
₹ crore by fiscal year